²¹²Pb-DOTAM-GRPR1
Phase 1Small molecule
²¹²Pb-DOTAM-GRPR1 is one of 9 small molecule programs targeting Recurrent or Metastatic. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
8
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
10 competitors in Recurrent or Metastatic
#DrugCompanyPhaseTrials
1Keytruda
Merck & Co.Phase 2
Taxotere
AAvyxa
Phase 2
Tuoyi
CCoherus Oncology, Inc.
Phase 2
Inlyta
PPrism Pharmaceuticals
Phase 2
Sacituzumab Tirumotecan
Merck & Co.Phase 2
SI-B001
SSichuan Baili Pharmaceutical Co., Ltd.
Phase 2
BL-B01D1
SSichuan Baili Pharmaceutical Co., Ltd.
Phase 2
Tagitanlimab
WWest China Hospital
Phase 2
²¹²Pb-DOTAM-GRPR1
OOrano Med LLC
Phase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for ²¹²Pb-DOTAM-GRPR1. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- OOrano Med LLC